...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Additional Reports Of Exempt Distribution.

given that rvx also issued securities to insiders as reported on SEDI, on June 4, 2024 it would appear that they weren't working on anything material up to that point? Our only hope of anything positive is that something material started shortly after June 4th hence the AGM being pushed out? - the way Don talks rvx has been trying to negotiate/in discussions/talks for months/years - not sure when "discussions/talks etc " become material??

Share
New Message
Please login to post a reply